Natural IgG autoantibodies are abundant and ubiquitous in human sera, and their number is influenced by age, gender, and disease
The presence of self-reactive IgG autoantibodies in human sera is largely thought to represent a breakdown in central tolerance and is typically regarded as a harbinger of autoimmune pathology. In the present study, immune-response profiling of human serum from 166 individuals via human protein micr...
Saved in:
Published in: | PloS one Vol. 8; no. 4; p. e60726 |
---|---|
Main Authors: | , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
Public Library of Science
02-04-2013
Public Library of Science (PLoS) |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | The presence of self-reactive IgG autoantibodies in human sera is largely thought to represent a breakdown in central tolerance and is typically regarded as a harbinger of autoimmune pathology. In the present study, immune-response profiling of human serum from 166 individuals via human protein microarrays demonstrates that IgG autoantibodies are abundant in all human serum, usually numbering in the thousands. These IgG autoantibodies bind to human antigens from organs and tissues all over the body and their serum diversity is strongly influenced by age, gender, and the presence of specific diseases. We also found that serum IgG autoantibody profiles are unique to an individual and remarkably stable over time. Similar profiles exist in rat and swine, suggesting conservation of this immunological feature among mammals. The number, diversity, and apparent evolutionary conservation of autoantibody profiles suggest that IgG autoantibodies have some important, as yet unrecognized, physiological function. We propose that IgG autoantibodies have evolved as an adaptive mechanism for debris-clearance, a function consistent with their apparent utility as diagnostic indicators of disease as already established for Alzheimer's and Parkinson's diseases. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Conceived and designed the experiments: EPN MH RGN. Performed the experiments: EPN MH NKA CD MCK. Analyzed the data: EPN MH NKA CD RGN. Contributed reagents/materials/analysis tools: RGN. Wrote the paper: EPN MH NKA RGN. Competing Interests: RGN is a stockholder in Durin Technologies, Inc., a small biotech company that is developing disease diagnostics using autoantibodies as biomarkers, and has filed patents on this technology. EPN is a paid consultant of Durin Technologies. This study was funded by the Foundation Venture Capital Group. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors. |
ISSN: | 1932-6203 1932-6203 |
DOI: | 10.1371/journal.pone.0060726 |